Patients’ characteristics who received NY-ESO-1-TCR-gene transduced lymphocyte transfer
| Cohort | Patient no | Age at entry (years) | Sex | HLA-A type | Disease | NY-ESO-1 expression (IHC %) | Tumor lesions at entry |
| 1 (5×108 cell dose) | 1 | Late 60s | F | 02:01 | Breast cancer | 5–<25 | Lung, lymph node |
| 2 | Early 40s | F | 02:01 | Synovial sarcoma | ≥75 | Lung | |
| 3 | Early 70s | M | 02:01 | Malignant salivary tumor | <5 | Primary lesion at parotid gland | |
| 2 (5×109 cell dose) | 7 | Late 40s | M | 02:01 | Synovial sarcoma | ≥75 | Soft tissue at femoral area, lung |
| 9 | Early 60s | M | 02:01 | Melanoma | ≥75 | Skin, liver, peritonium | |
| 8 | Early 70s | M | 02:01 | Synovial sarcoma | ≥75 | Chest wall, soft tissue at inguinal area, bone | |
| 14 | Late 60s | F | 02:06 | Ovarian cancer | 25–<50 | Lymph node | |
| 16 | Late 20s | M | 02:06 | Synovial sarcoma | ≥75 | Lung | |
| 15 | Late 40s | F | 02:01 | Myxoid liposarcoma | 50–<75 | Retroperitonium |
IHC, immunohistochemistry; TCR, T cell receptor.